Literature DB >> 21902063

Characterization of HIV-1 genotypes and antiretroviral drug-resistance mutations among patients in Burkina Faso.

T S Kagone1, H Hien, N Meda, P S Diagbouga, A Sawadogo, J Drabo, M Peeters, L Vergne, E Delaporte, C De Souza, M Gbeassor, J Simpore.   

Abstract

The purposes of this study were: (1) to describe the genetic variability of HIV strains found in Burkina Faso, (2) to characterize non-B HIV strains mutation profiles selected by ARVs and (3) to detect possible resistances induced by ARV drugs. From 30 October 2002 to 20 November 2003, 132 HIV 1-positive patients taking Highly Active Antiretroviral Therapy (HAART) for more than one year in Bobo-Dioulasso and Ouagadougou were included. T-CD4+ lymphocytes count was done using Dynabeads technique while genotypic test and ARV-resistance tests were conducted using Pol sequencing that codes for reverse transcriptase reverse, integrase and protease. Due to undetectable viremia, 86 samples out of 132 could not be characterized. Whereas in the 46 others that had a viral load exceeding 1000 copies mL(-1), the following HIV-1 subtypes were identified: CRF06 (54,55%); CRF02(38,63%); CRF01 (4,55%) and subtype A (2,27%). In addition, several mutations related to PI, NRTI and NNRTI resistance were isolated in 27 samples. This study found a huge genetic HIV-1 polymorphism in Burkina Faso. The level of acquired resistance to ARV after one year of treatment amounted 20.4%. These results clearly show that there is imperative need to set up an ARV resistance surveillance network in Burkina Faso to guide treatment strategies and follow the extension of the phenomenon in the country.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21902063     DOI: 10.3923/pjbs.2011.392.398

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  4 in total

1.  Prevention of mother-to-child HIV-1 transmission in Burkina Faso: evaluation of vertical transmission by PCR, molecular characterization of subtypes and determination of antiretroviral drugs resistance.

Authors:  Tani Sagna; Cyrille Bisseye; Tegewende R Compaore; Therese S Kagone; Florencia W Djigma; Djeneba Ouermi; Catherine M Pirkle; Moctar T A Zeba; Valerie J T Bazie; Zoenabo Douamba; Remy Moret; Virginio Pietra; Adjirita Koama; Charlemagne Gnoula; Joseph D Sia; Jean-Baptiste Nikiema; Jacques Simpore
Journal:  Glob Health Action       Date:  2015-01-27       Impact factor: 2.640

2.  APOBEC3G Variants and Protection against HIV-1 Infection in Burkina Faso.

Authors:  Tegwinde Rebeca Compaore; Serge Theophile Soubeiga; Abdoul Karim Ouattara; Dorcas Obiri-Yeboah; Damehan Tchelougou; Mamoudou Maiga; Maleki Assih; Cyrille Bisseye; Didier Bakouan; Issaka Pierre Compaore; Augustine Dembele; Jeremy Martinson; Jacques Simpore
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

3.  Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso.

Authors:  Serge Théophile Soubeiga; Bapio Valéry Jean Telesphore Elvira Bazie; Tegwindé Rebeca Compaore; Abdoul Karim Ouattara; Théodora Mahoukèdè Zohoncon; Dorcas Obiri-Yeboah; Albert Théophane Yonli; Arsène Zongo; Lassina Traore; Virginio Pietra; Simon Akpona; Serge Diagbouga; Jacques Simpore
Journal:  J Public Health Afr       Date:  2018-07-06

4.  APOBEC3G expression and HIV-1 infection in Burkina Faso.

Authors:  Tegwinde Rebeca Compaore; Serge Theophile Soubeiga; Abdoul Karim Ouattara; Damehan Tchelougou; Cyrille Bisseye; Didier Romuald Bakouan; Issaka Compaore; Augustine Dembele; Albert Theophane Yonli; Dorcas Obiri-Yeboah; Wendkuuni Florencia Djigma; Jacques Simpore
Journal:  J Public Health Afr       Date:  2018-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.